InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
3
Disclosed sells
0
T+90 hit rate
29%
T+90 mean return
+3.3%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Levitz Michael L, Chief Financial Officer. Insider active across 2 companies, notably Anika Therapeutics, Inc.. In total, 11 disclosures have been recorded. Breakdown: 3 buys · 0 sell. Total volume traded: €285k. Activity tracked since 10 August 2021. The latest transaction was disclosed on 11 March 2024 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations11 total
4,438 shares0Common StockSEC:0001171843-24-001304:0
3,859 shares0Common StockSEC:0001171843-23-005271:0
8,888 shares0Common StockSEC:0001171843-23-001686:0
4,439 shares0Common StockSEC:0001171843-23-001597:0
3,859 shares0Common StockSEC:0001171843-22-005617:0
4,000 shares@ US$24.6190.045% mcap47.8% of flowCommon StockSEC:0001171843-22-001832:0
Ideal exit: 6 Dec 2022 (T+270)
4,438 shares0Common StockSEC:0001171843-22-001812:0
2,850 shares@ US$40.2060.049% mcap52.2% of flowCommon StockSEC:0001171843-21-005933:0
Ideal exit: 8 May 2022 (T+270)
2,850 shares@ US$40.206100.0% of flowCommon StockSEC:0001171843-21-005933
Ideal exit: 8 May 2022 (T+270)
3,859 shares0Common StockSEC:0001171843-21-005897
3,859 shares0Common StockSEC:0001171843-21-005897:0
11 of 11 declarations
About Levitz Michael L
Michael L. Levitz is the Executive Vice President, Chief Financial Officer, and Treasurer of Anika Therapeutics, Inc. He oversees the financial management of the company, including budgeting and financial reporting. Michael plays a key role in Anika's financial strategy.
